The DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index.
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Open accessAbstract
Alzheimer’s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease,409,411 which are instructive for designing new drugs.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [409]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 2×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodInfluentialTrott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412 · cited 1×
“4 [8], and the data were interpreted using Discovery Studio [9] and UCSF Chimera [10].”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 2×
“Tau is a protein believed to play a significant role in the progression of AD; researchers are experimenting with several methods to target tau with the goal of altering the course of the disease [84].”
BackgroundResultAcetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · cited 1×
“Inflammation has now been observed in numerous investigations using postmortem tissues from samples of AD patients, but the role of inflammation in AD is not yet fully understood [91,92].”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“The amyloid cascade hypothesis is one of the signaling pathways that has been thoroughly investigated concerning AD [81].”
BackgroundAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Glutamate as a neurotransmitter in the healthy brain
Zhou, Y., & Danbolt, N. C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1180-8 · Cited by 979 · cited 1×
“Glutamate transmission modulation–glutamate is the most abundant excitatory neurotransmitter in the central nervous system, with about 40% of synapses containing it [67].”
BackgroundGlutamate receptor function in learning and memory
Riedel, G. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00272-3 · Cited by 962 · cited 1×
“Numerous preclinical studies have shown that when glutamate synapses are blocked, no new memories can form [68].”
BackgroundMicroglial Activation and its Implications in the Brain Diseases
Thameem Dheen, S., Kaur, C., & Ling, E.-A. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597961 · Cited by 952 · cited 1×
“These molecules cause damage to neurons, leading to the development of cognitive symptoms [93].”
Background
Research works printed but not linked: 3
- Wolfe, M.S. (2018). The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms, Academic Press.
- BIOVIA, 2017, BIOVIA Discovery Studio Visualizer, Softw. Version, 20, 779
- Darvesh, 1998, Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation, J. Comp. Neurol., 393, 374, 10.1002/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“51 These drugs primarily function by modulating neurotransmitter levels but cannot alter the course of the disease, 409,411 which are instructive for designing new drugs.”
BackgroundRamakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 192
Baran, M. F., Keskin, C., Baran, A., Hatipoğlu, A., Yıldıztekin, M., Küçükaydın, S., Kurt, K., Hoşgören, H., Sarker, M. M. R., Sufianov, A. A., et al. (2023) · Molecules · doi:10.3390/molecules28052310 · Cited by 159
Diet and lifestyle impact the development and progression of Alzheimer’s dementia
Arora, S., Santiago, J. A., Bernstein, M., & Potashkin, J. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1213223 · Cited by 113
Song, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114647 · Cited by 97
Metadata
- Authors
- Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M.
- Affiliations
- University of Oradea (RO)
- University of Petroleum and Energy Studies (IN)
- Shanghai Jiao Tong University (CN)
- Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania
- Corresponding author
- Negru, Paul Andrei
- Bungau, Simona Gabriela
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2022-12-28
- Volume
- 12
- Issue
- 1
- Pages
- 131
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC9818415
- OpenAlex
- W4313361457
- Cited by
- 96
- References
- 124
- Citations by year
- 2026: 25 · 2025: 26 · 2024: 28 · 2023: 17
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Romanian Ministry of Research, Innovation and Digitisation (29 PFE/30.12.2021)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, pharmacotherapy, cholinesterase inhibitors, glutamate receptor antagonists, disease-modifying therapy, dementia, molecular docking, drug development, cognitive impairment
- MeSH terms
- Aged, Alzheimer Disease, Cholinesterase Inhibitors, Humans, Molecular Docking Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. https://app.cochat.ai/papers/10.3390/cells12010131
- The paper
- Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022). Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells. https://doi.org/10.3390/cells12010131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.